nivolumab,ipilimumab
bms
['nivolumab', 'lcsm,(-blcsm)', '9la', 'nivo', 'ipilimumab', 'check,mate,9la', 'nsclc', 'sclc']
in the phase 3 checkmate 9la trial, patients with advanced #nsclc derived durable benefit from first-line treatment with nivolumab + ipilimumab. #asco2023 #lcsm | 
Oncology news and insights from leading researchers and cancer centers.